ArticleCancer research2008
Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Genome-wide association study of colorectal cancer identifies six new susceptibility loci.Nature communications · 2015Pooled it
- LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia.PloS one · 2014Trial
- ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer.World journal of surgical oncology · 2026Article
- A novel lipophilic amiloride derivative efficiently kills chemoresistant breast cancer cells.Scientific reports · 2024Article
- Article
- Neighborhood Deprivation and DNA Methylation and Expression of Cancer Genes in Breast Tumors.JAMA network open · 2023Article
- High-throughput functional screen identifies YWHAZ as a key regulator of pancreatic cancer metastasis.Cell death & disease · 2023Article
- Vangl-dependent Wnt/planar cell polarity signaling mediates collective breast carcinoma motility and distant metastasis.Breast cancer research : BCR · 2023Article
- Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.British journal of cancer · 2022Article
- LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.Seminars in cancer biology · 2022Review
- Article
- Article
- In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift.Biomaterials · 2022Article
- Optimization of microbubble-based DNA vaccination with low-frequency ultrasound for enhanced cancer immunotherapy.Advanced therapeutics · 2021Article
- The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.Molecular oncology · 2021Article
- miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.Cell death & disease · 2021Article
- Review
- Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Low-frequency ultrasound-mediated cytokine transfection enhances T cell recruitment at local and distant tumor sites.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer.BMC cancer · 2020Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The ErbB2 receptor tyrosine kinase is overexpressed in approximately 25% of breast tumors and contributes to poor patient prognosis and therapeutic resistance. Here, we examine the role of the recently discovered ErbB negative regulator LRIG1 in ErbB2(+) breast cancer. We observe that LRIG1 protein levels are significantly suppressed in ErbB2-induced mammary tumors in transgenic mice as well as in the majority of ErbB2(+) human breast tumors. These observations raise the possibility that LRIG1 loss could contribute to the initiation or growth of ErbB2(+) breast tumors. RNA interference-mediated knockdown of endogenous LRIG1 in the ErbB2-overexpressing breast tumor cell lines MDA-MB-453 and BT474 further elevates ErbB2 in these cells and augments cellular proliferation. In contrast, ectopic expression of LRIG1 reverses these trends. Interestingly, we observe that LRIG1 protein levels are suppressed in response to ErbB receptor activation in breast tumor cells but are unaffected by ErbB activation in immortalized nontransformed breast epithelial cells. Our observations indicate that the suppression of LRIG1 protein levels is a common feature of breast tumors. Moreover, our observations point to the existence of a feed-forward regulatory loop in breast tumor cells where aberrant ErbB2 signaling suppresses LRIG1 protein levels, which in turn contributes to ErbB2 overexpression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.